stockrow
Friday 6 November 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million.
- EPS
- +1.30%
- Free cash flow
- +50.2%
Quarter to June 2026, against a year earlier
34.24
1.71
+5.26%
Follow MAZE
Alert me
Maze Therapeutics, Inc. (MAZE) P/E ratio
Maze Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)